BPC-157

BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid peptide (a pentadecapeptide) derived from a partial sequence of a protein naturally present in human gastric juice, first isolated and characterized by Croatian gastroenterologist and researcher Predrag Sikiric and colleagues beginning in the early 1990s. It was developed initially as a laboratory tool to investigate the gut's own protective and repair mechanisms and has since become one of the most extensively studied compounds in the "research peptide" category, with several hundred published preclinical studies, the overwhelming majority conducted in rodents and produced by a relatively concentrated set of research groups centered in Croatia. BPC-157 has never completed human clinical trials and is not approved as a drug by the FDA, the EMA, or any comparable regulator anywhere in the world. It is sold in the United States exclusively under a "research use only" label, a designation intended to restrict its sale and use to laboratory research settings and that explicitly excludes human consumption, though it is nonetheless widely purchased and self-administered by athletes, bodybuilders, and biohackers seeking faster recovery from soft-tissue injury, obtained through online vendors with no pharmaceutical-grade quality assurance.

The proposed mechanism of BPC-157 centers on angiogenesis and growth-factor pathway modulation. In vitro and rodent studies suggest that the peptide upregulates VEGFR2, the primary receptor for vascular endothelial growth factor, activating downstream Akt and endothelial nitric oxide synthase (eNOS) signaling that together promote new blood vessel formation at sites of tissue injury. Separately, rodent tendon studies have found that BPC-157 modulates growth-hormone-receptor expression in tendon fibroblasts, and cell-culture work has shown that it promotes migration and proliferation of fibroblasts, myoblasts, and endothelial cells, all cell types central to wound healing. Several studies have found that co-administering nitric oxide synthase inhibitors blunts BPC-157's protective effects in rodent models, implicating nitric oxide signaling as at least partly necessary for its activity. Despite this substantial body of proposed mechanistic detail, no specific, cloned cell-surface receptor for BPC-157 has been definitively identified, leaving open the possibility that its effects arise from a combination of pathways rather than a single primary target.

The strongest and most extensively replicated preclinical evidence for BPC-157 spans three domains. In musculoskeletal healing, rat models of surgically transected Achilles tendon, torn medial collateral ligament, and crushed quadriceps muscle have consistently shown accelerated functional recovery and improved tensile strength with BPC-157 treatment compared with untreated injured controls. In gastrointestinal protection, dozens of rodent studies have found that BPC-157 reduces the size of experimentally induced gastric and duodenal ulcers, accelerates healing of chemically induced colitis, and protects gastric mucosa against alcohol- and NSAID-induced damage, an effect consistent with its origin as a fragment of a gastroprotective gastric-juice protein. In neural repair, rat models of peripheral nerve crush injury and spinal cord injury have shown improved functional and histological recovery with BPC-157 treatment. Across all three domains, the evidence is exclusively preclinical: no randomized controlled human trial has tested BPC-157 for tendon injury, inflammatory bowel disease, or nerve injury, and the gap between this large animal literature and the complete absence of human trial data is the single most important fact governing any responsible discussion of the compound.

From a regulatory and practical standpoint, BPC-157 occupies an unusual and precarious position. In 2023, the FDA formally placed BPC-157 on its list of bulk drug substances that outsourcing facilities and compounding pharmacies may not use in compounded human drug products, citing an absence of adequate data to establish a substance's safety, among other concerns, a decision that closed off what had been a route by which some compounding pharmacies were providing it under physician prescription in the United States. It remains legally available as a "research use only" laboratory chemical, a category that exists for legitimate scientific research use and that vendors and buyers use as a workaround for what is, in practice, human self-administration. This gray-market status means purchased product carries no guarantee of correct peptide sequence, purity, sterility, or accurate concentration, and independent testing of research-peptide vendors has repeatedly found meaningful discrepancies between labeled and actual content. Anyone considering BPC-157 should weigh this regulatory reality, and the complete absence of human trial data, against the extensive marketing built around the rodent literature.

Mechanism of Action

Angiogenic Signaling (VEGFR2-Akt-eNOS)

The most extensively proposed mechanism for BPC-157 centers on angiogenesis, the formation of new blood vessels, which is essential to nearly every stage of tissue repair. In rodent and cell-culture studies, BPC-157 has been shown to upregulate VEGFR2, the principal receptor for vascular endothelial growth factor on endothelial cells, and to activate the downstream Akt and endothelial nitric oxide synthase (eNOS) signaling cascade that follows VEGFR2 activation. This cascade promotes endothelial cell survival, migration, and the formation of new capillary networks at sites of injury, which in turn improves local blood supply, oxygen delivery, and nutrient availability for repairing tissue. Several rodent studies have found that co-administering nitric oxide synthase inhibitors blunts the peptide’s protective effects across multiple injury models (tendon, gut, and nerve), suggesting that nitric oxide-dependent signaling downstream of this pathway is functionally important rather than incidental to the observed effects. This angiogenic mechanism is proposed as a shared thread connecting BPC-157’s effects across otherwise very different tissue types.

Growth-Factor and Cytoskeletal Effects

Beyond angiogenesis, in vitro studies using cultured tendon fibroblasts have found that BPC-157 modulates expression of growth-hormone-receptor signaling components and promotes fibroblast proliferation and migration, cellular behaviors central to forming new, organized collagen matrix at an injury site. Parallel cell-culture work in myoblasts (muscle precursor cells) has found similar pro-proliferative and pro-migratory effects, proposed to underlie the accelerated functional recovery seen in rat muscle-crush injury models. These growth-factor and cytoskeletal effects appear to act in parallel with, rather than purely downstream of, the angiogenic pathway, since some in vitro effects have been observed in isolated cell cultures without a vascular component present.

Gastrointestinal Cytoprotection

Consistent with its origin as a fragment of a naturally gastroprotective gastric-juice protein, BPC-157 has shown protective and healing-accelerating effects across a wide range of rodent gastrointestinal injury models, including chemically induced gastric and duodenal ulcers, alcohol-induced gastric mucosal damage, NSAID-induced gastric injury, and experimentally induced colitis. Proposed mechanisms include preservation of mucosal blood flow (an extension of the angiogenic and nitric oxide effects described above), modulation of prostaglandin signaling, and direct cytoprotective effects on gastric epithelial cells. This gastrointestinal-protection literature is arguably the most consistently replicated body of BPC-157 research, spanning multiple research groups and injury models, though it remains confined to rodents and has not been tested in a human inflammatory bowel disease or ulcer trial.

Evidence Limitations

Despite the volume and apparent mechanistic coherence of the preclinical literature summarized above, several important limitations apply. No specific, cloned, human cell-surface receptor for BPC-157 has been definitively identified, meaning the “mechanism” described here is a set of observed downstream signaling changes rather than a confirmed ligand-receptor interaction of the kind established for peptides like GLP-1 or growth-hormone-releasing hormone analogs. The great majority of published studies originate from a relatively small, geographically concentrated set of research groups, predominantly the peptide’s original discoverers, which narrows the independence of replication compared with peptides studied across many unrelated laboratories worldwide. And critically, every mechanism described in this section is inferred from rodent tissue, rodent whole-animal models, or cultured cells; none of it has been confirmed to operate the same way, at the same doses, in living human tissue.

Clinical Evidence

Musculoskeletal Injury Models

The largest single category of BPC-157 preclinical research covers musculoskeletal injury. Rat models of surgically transected Achilles tendon have repeatedly found accelerated functional recovery and improved tensile strength of the healing tendon with BPC-157 treatment compared with untreated controls, and similar accelerated-healing findings have been reported in rat models of torn medial collateral ligament and crushed quadriceps muscle. These studies use standardized surgical injury models and objective biomechanical testing, which strengthens their internal validity as animal experiments, but none has been replicated in a human tendon, ligament, or muscle injury trial of any design or size.

Gastrointestinal Disease Models

A separate, large body of rodent research has examined BPC-157 in models of gastric and duodenal ulceration, alcohol- and NSAID-induced gastric mucosal injury, and chemically induced colitis, generally finding reduced lesion size and accelerated mucosal healing compared with untreated animals. This gastrointestinal-protection literature is the area where BPC-157’s proposed mechanism (a gastric-juice-protein fragment) most directly matches the model being tested, and it represents some of the earliest and most frequently cited BPC-157 research. As with the musculoskeletal literature, however, no human trial has tested BPC-157 in patients with peptic ulcer disease, inflammatory bowel disease, or NSAID-induced gastropathy.

Neural Repair Models

Rat models of peripheral sciatic nerve crush or transection injury, and separate rat spinal cord injury models, have found improved functional recovery scores and histological measures of nerve regeneration with BPC-157 treatment compared with untreated injured controls. This body of evidence is smaller than the tendon and gastrointestinal literature but has generated interest in potential neuroprotective applications. It remains, like the rest of the BPC-157 evidence base, confined entirely to rodent models.

Human Evidence Gap (State of the Evidence)

No randomized controlled human trial of BPC-157 has been completed for any indication as of this writing. This stands in sharp contrast to the several hundred published rodent and cell-culture studies on the compound and to its considerable popularity as a self-administered “research peptide” among athletes and biohackers seeking faster recovery from tendon, ligament, and muscle injuries. Everything currently claimed about BPC-157’s effects in humans, whether in online community reports, gray-market vendor marketing, or informal physician use, is extrapolated from animal data or drawn from uncontrolled, unblinded self-reports, neither of which can establish human efficacy, an appropriate human dose, or a genuine human safety profile. Readers should treat any claim of “proven” human benefit for BPC-157 with the understanding that the underlying clinical trials simply do not exist yet.

Safety and Tolerability

Acute toxicology testing conducted by the peptide’s original research groups in rodents reported a favorable safety profile at the doses studied, and anecdotal community reports describe injection-site irritation as the most commonly noted adverse effect with self-administered use, consistent with the pattern seen across most self-injected research peptides. However, no systematic human adverse-event surveillance exists for BPC-157, and the FDA’s 2023 determination that BPC-157 lacks adequate safety data to support compounding reflects a regulatory judgment that available toxicology and safety information falls short of what would be required before broader human use, including uncertainty around chronic administration and around the theoretical angiogenesis-related risks discussed elsewhere on this page. Product quality is a separate, compounding safety concern: because BPC-157 is sold as an unregulated “research use only” chemical, purchased material may not match its label in identity, purity, or concentration.

Regulatory Status

BPC-157 is not approved as a drug for any indication by the FDA, the EMA, or any comparable regulatory body worldwide, and it has never completed the clinical trial process required for pharmaceutical approval. In 2023, the FDA placed BPC-157 on its Category 2 list of bulk drug substances that outsourcing facilities and compounding pharmacies are prohibited from using in compounded human drug products, citing significant safety concerns including inadequate data to establish a safety profile; this closed off a compounding-pharmacy pathway through which some patients had previously obtained it by prescription in the United States. It remains legally sold as a “research use only” laboratory chemical, a designation intended for legitimate scientific research that explicitly excludes human consumption, though enforcement against individual human use has been limited in practice. BPC-157 is not currently named on the World Anti-Doping Agency Prohibited List in the specific way some growth-hormone secretagogues are, though its use by competitive athletes carries reputational and, depending on the sporting body’s specific rules regarding unapproved substances, potential eligibility risk. Anyone encountering BPC-157 marketed as a supplement, a compounded prescription, or an approved therapeutic anywhere in the world should treat that claim with skepticism given its actual regulatory status.

Dosing Guidance

Rodent studies have used systemic BPC-157 doses generally in the range of approximately 1 to 10 micrograms per kilogram body weight for intraperitoneal or subcutaneous administration, with considerably higher local or oral concentrations used in some gastrointestinal-protection experiments, and no single dosing protocol standardized across the animal literature. No human dose-ranging study of any kind has been conducted, so doses circulating in online community protocols, typically in the range of a few hundred micrograms per day, are extrapolated from animal body-weight scaling assumptions rather than derived from validated human pharmacology or safety data. These community-reported doses should be understood as unverified self-experimentation figures, not as an established or clinically validated therapeutic dose.

BPC-157 versus TB-500

BPC-157 and TB-500 are frequently combined in community “healing stack” protocols and are often discussed together because both are unapproved, research-only peptides marketed for accelerating soft-tissue injury recovery, but they are structurally and mechanistically distinct. BPC-157 is a 15-amino-acid gastric-juice-derived peptide whose proposed activity centers on VEGFR2-mediated angiogenesis and gastrointestinal cytoprotection. TB-500 is a synthetic fragment of thymosin beta-4, a naturally occurring actin-regulating protein, whose proposed activity centers on actin-binding-mediated cell migration rather than angiogenesis specifically. No controlled study, animal or human, has evaluated whether combining the two peptides produces additive, synergistic in the strict biochemical sense, or simply independent effects, and the popularity of combining them in community protocols reflects shared marketing and anecdote rather than a validated combination rationale.